GSC
TCRT icon

Ground Swell Capital’s Alaunos Therapeutics TCRT Stock Holding History

Ground Swell Capital’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-54
Closed -$33K – 2755
2014
Q2 		$33K Buy
+54
New +$30.1K 0.06% 253

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ground Swell Capital's TCRT Position: Q3 2014 in Review

Ground Swell Capital sold out of Alaunos Therapeutics (TCRT) in Q3 2014, closing a stake of 54 shares — an estimated $33K sold.

Ground Swell Capital first reported a position in TCRT in Q2 2014 and held it in 1 quarter. The position peaked at $33K in Q2 2014. 94 funds tracked by Wall St. Rank hold TCRT as of Q3 2014.

  • Ground Swell Capital reported no remaining Alaunos Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 54 Alaunos Therapeutics shares in Q3 2014, an estimated $33K.
  • Ground Swell Capital first reported a position in Alaunos Therapeutics in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Alaunos Therapeutics position peaked at $33K in Q2 2014.
  • 94 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.